DICE Therapeutics Inc is a biopharmaceutical company leveraging proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas.
Quote | DICE Therapeutics Inc. (NASDAQ:DICE)
Last: | $47.55 |
---|---|
Change Percent: | -0.08% |
Open: | $47.59 |
Close: | $47.55 |
High: | $47.8301 |
Low: | $47.46 |
Volume: | 4,332,950 |
Last Trade Date Time: | 08/08/2023 03:00:00 am |
News | DICE Therapeutics Inc. (NASDAQ:DICE)
BiondVax (NASDAQ: BVXV) , a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently recei...
2023-08-09 18:43:54 ET Stifel has downgraded Morphic ( NASDAQ: MORF ) to hold, stating that it believes open-label data for its anti-inflammatory drug candidate MORF-057 isn't enough to score a near-term M&A deal. Stifel said that while the immunology and inflammation space ...
Message Board Posts | DICE Therapeutics Inc. (NASDAQ:DICE)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
DICE Therapeutics Inc. Company Name:
DICE Stock Symbol:
NASDAQ Market:
DICE Therapeutics Inc. Website:
BiondVax (NASDAQ: BVXV) , a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently recei...
Lilly Completes Acquisition of DICE Therapeutics PR Newswire INDIANAPOLIS , Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition...
BiondVax, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, was featured in a recent analyst report reiterating a Buy recommendation and a $70 target price The report discussed Eli Lilly’s announcement of a definitive...